Core Viewpoint - The company, Olin Bio, is planning to issue overseas shares (H-shares) and apply for listing on the Hong Kong Stock Exchange to enhance its international presence and optimize its capital structure [2] Group 1: Company Strategy - The company aims to deepen its international strategic layout and increase its global recognition and influence [2] - The initiative is part of a broader effort to strengthen the company's overall competitive capabilities [2] Group 2: Listing Process - Currently, the company is in discussions with relevant intermediaries regarding the H-share listing [2] - Specific details about the H-share listing are yet to be determined [2] - The listing process will require approval from the company's board and shareholders, as well as regulatory approvals from the China Securities Regulatory Commission, Hong Kong Stock Exchange, and the Securities and Futures Commission of Hong Kong [2]

Group 1 - The company, Olin Bio (688319.SH), is planning to issue overseas shares (H-shares) and apply for listing on the Hong Kong Stock Exchange to enhance its international presence and influence [1] - This initiative is part of the company's strategy to deepen its internationalization and optimize its capital structure [1] - The goal is to strengthen the company's overall competitiveness in the market [1]